Citation

Fornaro M, De Berardis D, Anastasia A, Fusco A. Adv. Exp. Med. Biol. 2021; 1305: 449-461.

Copyright

(Copyright © 2021, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/978-981-33-6044-0_22

PMID

unavailable

Abstract

Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.

Language: en

Keywords

Ketamine; Major depressive disorder; Esketamine; Novel antidepressant; Treatment resistance